Rigel outlines $290M-$295M 2026 revenue outlook as VEPPANU launch starts with $6.6M sales

Earnings Call Insights: Rigel Pharmaceuticals (RIGL) Q3 2026

Management View

• "We delivered over $72 million in net product sales, our highest ever and another profitable quarter" (President, CEO & Director Raul Rodriguez).
• "VEPPANU became commercially available in the U.S. on August

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.